Abstract
AbstractThis randomized, double-blind, placebo-controlled, multiple ascending–dose study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of milvexian, an oral small-molecule FXIa inhibitor, in healthy Japanese participants. Participants received oral milvexian daily under fasted (50 mg and 200 mg) or fed conditions (500 mg) or placebo over 14 days; 24 participants (8/cohort: 6 milvexian; 2 placebo) were planned. Due to an unblinding event, participants in one cohort (200 mg daily) were discontinued, and a second cohort enrolled; 32 participants were included in safety and pharmacodynamic analyses, and 24/32 in pharmacokinetic analyses. Milvexian up to 500 mg daily for 14 days was generally well tolerated, with no deaths, serious adverse events, or discontinuations due to adverse events. Milvexian exposure increased between 50-mg and 200-mg doses. Median Tmax was similar with 50-mg and 200-mg doses (2.5–3.0 h) and delayed under fed conditions (500 mg, 7.0–8.0 h). Median T1/2 was similar across doses (8.9–11.9 h). Multiple oral milvexian administrations resulted in concentration-related prolongation of aPTT and decreased FXI clotting activity.
Milvexian was generally safe and well tolerated. The pharmacokinetic and pharmacodynamic profile of milvexian demonstrates suitability for further clinical development in Japanese participants.
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Cavallari, I. & Patti, G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol. J. Cardiol. 19, 67–71 (2018).
2. Kapil, N. et al. Antiplatelet and anticoagulant therapies for prevention of ischemic stroke. Clin. Appl. Thromb. Hemost. 23, 301–318 (2017).
3. Gurbel, P. A., Fox, K. A., Tantry, U. S., Ten Cate, H. & Weitz, J. I. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation 139, 2170–2185 (2019).
4. Eisen, A., Giugliano, R. P. & Braunwald, E. Updates on acute coronary syndrome: A review. JAMA Cardiol. 1, 718–730 (2016).
5. Faxon, D. P. Use of antiplatelet agents and anticoagulants for cardiovascular disease: Current standards and best practices. Rev. Cardiovasc. Med. 6(suppl 4), S3–S14 (2005).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献